Date: 2016-07-28
Type of information: Capital increase
Company: Nicox (France)
Investors:
Amount: €18 million
Funding type: capital increase
Planned used: The proceeds from the financing will principally be used to drive the development of NCX 4251, a nanocrystalline
formulation of fluticasone for blepharitis, and of NCX 470, a nitric oxide (NO)-donating bimatoprost for
intraocular pressure lowering, through proof-of-concept clinical studies.
NCX 4251 is currently in formulation development. Nicox currently plans to seek a pre- Investigational New Drug (IND) meeting, to be held by the end of Q1 2017, and also expects to start clinical studies directly at Phase 2 in 2017.
NCX 470 is currently in pre- IND toxicology studies. Nicox currently plans to seek a pre-IND meeting, to be held by the end of Q1 2017, and also expects to start clinical studies directly at Phase 2 in H2 2017.
Others: * On July 28, 2016, Nicox announced a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds of the financing are approximately €18 million, for a total of 2,064,000 million new shares, which represents the maximum capital increase the Company could undertake without publishing a formal prospectus. The financing attracted significant investor interest which exceeded the maximum offering size.
The share capital increase, by issuance of 2,064,000 million new ordinary shares was reserved for subscription by French or foreign companies or mutual funds investing in the pharmaceutical biotechnology sector (sociétés ou fonds gestionnaires d’épargne collective de droit français ou de droit étranger investissant dans le secteur pharmaceutique/biotechnologique).
Therapeutic area: Ophtalmological diseases
